Introduction
Percutaneous mitral balloon valvuloplasty (PMBV) has been developed as an alternative modality to surgical closed commissurotomy for mitral stenosis (MS) (1) , and excellent hemodynamic improvement with favorable outcome has been reported by many investigators (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . Although numerous studies have documented favorable immediate and intermediate-term results, long-term echocardiographic follow-up studies are rare (1) (2) (3) (4) (5) (6) (10) (11) (12) (13) .
In addition, cumulative clinical experience shows that restenosis and late functional deterioration developing 5 years after PMBV can be potentially important clinical dilemma, especially when discussing indications for PMBV (9) . Restenosis rate after PMBV has been reported to range from 3% to 70% at 1-3 years (10) (11) (12) .
The purpose of this study was to determine the acute and longterm clinical and echocardiographic results of consecutive patients who underwent PMBV at a single institution. These data were analyzed to identify factors influencing the long-term outcome.
Methods

Study design and population
In this single-center study, we retrospectively evaluated consecutive 311 patients (66 male and 245 female with a mean age of 36.2±9.7 years) who underwent PMBV in our Cardiology Clinic, Türkiye Yüksek İhtisas Education and Research Hospital for symptomatic moderate or severe MS between January 2000 and March 2004. A follow-up program beyond five years was scheduled. We contacted 311 patients either by phone or letter at least 5 years after the procedure. These patients were questioned about the functional status and for the primary endpoints (death, rePMBV, mitral valve replacement (MVR). Eighty-seven of 311 patients who defined New York Heart Association (NYHA) class II-IV symptoms were invited for a control visit and detailed echocardiographic evaluation.
After getting local Ethics Committee approval, a written informed consent was obtained from all patients, who accepted to participate. Sixty-three of 87 patients with NYHA class II-IV symptoms accepted to attend control visit and were evaluated by detailed echocardiographic examination for long-term consequences.
Those 63 patients were subclassified into two groups as those with uneventful (n=26) and those with re-narrowing of the mitral valve area (MVA) (<1.5 cm 2 ), rePMBV or referral to MVR (n=37) on follow up to 6.4±1.6 years.
Baseline clinical and follow-up variables
We noted the subjects' clinical and demographic characteristics, which included age, sex, body mass index, history of arterial hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg), diabetes mellitus, NYHA functional status, medications, the period of time after PMBV procedure and interventions during the period after PMBV.
The 12-lead ECGs were obtained at the standard article speed of 25 mm/s and calibration of 10 mm/mV from all of the patients and cardiac rhythms were recorded.
Echocardiographic and Doppler examinations
Two-dimensional and Doppler echocardiographic studies were performed before and after the procedure in all patients and in 67 patients at control visit by using a Vivid 7 Pro cardiac ultrasound system (General Electric, Horten, Norway) with appropriate probe. In addition to transmitral gradient (MG) and the peak transmitral gradient (PG), mitral valve area (MVA) was calculated from the Doppler study (using the pressure half-time method) and also by planimetry of the mitral valve orifice in parasternal short-axis view. Systolic pulmonary arterial pressure (SPAP) was estimated by continuous wave Doppler interrogation of the tricuspid regurgitant jet, using the modified Bernoulli equation.
Morphological features of the mitral valve were semi-quantified according to mitral Wilkins score (MWS), which was obtained by adding the scores of each of the following individual morphologic features: leaflet mobility, thickness, calcification, and subvalvular lesions (14) . Mitral and tricuspid regurgitation (TR) were graded from 0 to 4+, depending on the spatial extent of the color flow jet area expressed as a percentage of left and right atrial area. Each patient served as their own control. All patients underwent PMBV using the stepwise Inoue balloon technique as described previously (1) . All transseptal punctures were performed by an experienced operator. Standard hemodynamic measurements of right and left heart pressures were performed; simultaneous measurements of left atrial and left ventricular pressures were also done. Mean mitral gradient and MVA were calculated using the Gorlin formula; cardiac output was determined by Fick or thermodilution method. All hemodynamic measurements were obtained before and immediately after PMBV.
Percutaneous mitral balloon valvuloplasty
The PMBV was considered successful if the MVA was >1.5 cm 2 without grade 3-4 MR in Doppler study.
Long-term follow-up
Sixty-three patients were followed up for 6.4±1.6 years. Event-free survival was defined as no death, MVR, rePMBV or NYHA class III or IV symptoms. Restenosis was defined as >50% loss of the original increase in MVA, with follow-up MVA <1.5 cm 2 . Clinical evaluation was accomplished by direct interview at clinic rounds. At the follow-up visit, exercise capacity was evaluated according to NYHA functional classification and echocardiography, including the assessment of MVA and pressure gradient was performed.
Statistical analysis
Statistical analysis was performed using SPSS software (14.0 for Windows; SPSS Inc, Chicago, Ill, USA). Parametric variables are expressed as mean±standard deviation, and categorical variables are expressed as percent. Independent parametric variables were compared via independent sample's t-test, and categorical data with Chi-square test. Temporal change of parametric variables were studied via paired samples' t-test. All patients regardless of successful PMBV were included in the analysis. Parameters that achieved a significance level of p less than 0.20 were incorporated in a multivariate logistic regression model.
Kaplan-Meier estimates were used to determine event-free survival in the group of patients who gave informed consent for follow up (freedom from death, MVR, or redo PMBV). Comparison between groups was performed using the log rank test.
Results
Baseline characteristics and immediate outcomes
The study involved a total of 311 patients, comprising 63 long term clinical and echocardiographic follow-up patients. All 311 patients were divided into two groups due to acute postprocedural results as successful PMBV (MVA 1.5 cm 2 or greater with post-PMBV MR grade <3) (Group 1) and unsuccessful PMBV (Group 2). All patients underwent successful septostomy and mitral valves were passed by balloon. Acute success was obtained in 293 patients (94%). Eighteen inadequate immediate results were related to suboptimal valve opening (valve area < 1.5 cm 2 ) in 13 cases (4.18%) and severe MR (grade ≥3) in 5 cases (1.6%). These 18 patients with suboptimal results were not included into further long-term analysis. Preprocedural clinical, echocardiographic and hemodynamic characteristics of two groups are shown in Table 1 . Preprocedural rhythm was atrial fibrillation (AF) in 47 patients. At the end of procedure, 4 patients turned into sinus rhythm, whereas, new onset AF was observed in 8 patients.
Baseline clinical, echocardiographic and hemodynamic parameters were similar between groups except for preprocedural MVA which was significantly lower in unsuccessful group (p=0.008). Scores of subvalvular thickening (p=0.656), leaflet mobility (p=0.212), leaflet thickening (p=0.333), leaflet calcification (p=0.617) were also similar between groups.
Predictors of acute procedural PMBV success In the 311 procedures, preprocedural variables were evaluated by univariate analysis as predictors of PMBV success. Complete information was available in all procedures. Only preprocedural MVA was statistically significant predictor of acute procedural success in the univariate analysis ( Echocardiographic MG, PG, SPAP and MG in catheterization decreased significantly after valvuloplasty, with a corresponding increase in MVA measured at echocardiography and cardiac catheterization ( Table 2) .
There were no deaths, pericardial tamponade and cerebrovascular accident (CVA) in postprocedural hospitalization period. Access site complications were noticed in 4 patients (1.28%) as localized hematoma. There was no venous thrombosis in any of the patients. Postprocedural severe MR (grade ≥3) was detected in 5 patients. Two of 5 underwent operation at long term follow-up.
Long-term outcomes
Two deaths occurred at follow-up, one died after a large cerebral infarction following cerebral embolism in the setting of AF 6 months later the procedure and one died following end stage renal failure deemed unrelated to his cardiac condition 14 months later the procedure. Fourteen out of 293 patients who developed NYHA III-IV symptoms underwent reintervention for severe symptomatic restenosis (redo PMBV in 6 patients and MVR in 8 patients). Six patients were in NYHA functional class III-IV and still awaiting reintervention.
In the long term follow up of 63 patients, baseline clinical and biochemical parameters were similar between groups (Table 3) .
Baseline echocardiographic characteristics of the groups were similar between groups except for PG which was significantly lower in Group 1 (p=0.009) and percent improvement in MVA after PMBV in acute phase which was significantly lower in group 2 (56% vs. 80%, p<0.001). Patients with uneventful course (Group 1) had significantly higher MVA (p<0.001) and lower mean (p=0.001) and peak transmitral gradients (p<0.001) immediately after the procedure when we compared to the patients in Group 2.
When patients, who underwent echocardiographic examination for long-term follow-up, were classified according to presence or absence of at least 60% improvement in MVA after the procedure, there was a significant difference in between the two groups with reference to composite event, defined as renarrowing of the valve, reintervention to valve either with surgery or rePMBV. Overall, 42.5% of those with at least 60% improvement <0.001 after follow-up, % Data are expressed as mean±standard deviation and number *independent sample's t-test and Chi-square test BMI -body-mass index, EF -ejection fraction, GFR -glomerular filtration rate, M/F -male/ female, MG -mean transmitral gradient, MPAP -mean pulmonary artery pressure, MVA -mitral valve area, MWS -mitral Wilkins score, NYHA -New York Heart Association, PG -peak transmitral gradient, SPAP -systolic pulmonary artery pressure Table 3 . Clinical, biochemical and echocardiographic parameters of long-term follow-up groups in MVA experienced composite event during follow-up, whereas, 87% of those with less than 60% improvement in MVA experienced composite end-point (p=0.001). When patients (n=63) were compared according to cumulative event free survival (including those without reMVR or rePMBV), it was noticed that patients with at least 60% improvement in MVA experienced composite end-point much less frequently compared to those with less than 60% improvement in MVA (5% vs. 30.4%, p=0.009).
Kaplan-Meier analysis yielded significantly diverging cumulative survival curves for those with and without at least 60% improvement in MVA (Fig. 1) .
Discussion
Our results showed that, while preprocedural MVA was associated with immediate procedural success, percent improvement in MVA with the procedure might predict the restenosis of mitral valve in the long-term.
PMBV is the procedure of choice to treat rheumatic MS in the majority of patients with moderate or severe MS who are symptomatic or have pulmonary hypertension. Rifaie et al. (15) showed that PMBV achieves comparable results to closed surgical commissurotomy both in the short and long-term. Careful patient selection, however, is necessary to achieve a successful outcome.
Predictors of immediate procedural results have been analyzed in prior series and indicate that determinants of success are multifactorial (1) (2) (3) (4) (5) (6) (10) (11) (12) (13) . Early risk scores were comprised of semi quantitative assessment of leaflet thickening, subvalvular change, leaflet mobility, and valve calcification, and thus initial procedural experience was limited to patients with pliable, noncalcified mitral valves (14) . Although MWS correlates with PMBV results, their utility when considered in isolation has been challenged (16) . Percutaneous mitral balloon valvuloplasty is frequently performed on patients previously considered poor candidates by echocardiographic score with acceptable results at the present day (7, 17) . Furthermore, Güray et al. (18) was shown that PMBV after closed mitral commissurotomy was an effective alternative treatment of MS.
In our study, although MWS of 38 of total 311 patients was >8, acute postprocedural success was nearly 95% and was significantly higher than those in previous studies (17, 19) . However, a new scoring system which was suggested by Rifaie may be more reliable and correlates with outcome better than the standard scoring system (20) .
As a difference from previous studies which were concluded that the predictive value of combined clinical, echocardiographic, and hemodynamic parameters (7, 12, 14, 21) , we identified that only preprocedural MVA assessed by echocardiography is a significant predictor of immediate procedural results. Importantly, in the subgroup of patients with less favorable anatomy by echocardiographic score (score >8), who are often excluded from undergoing PMBV on this basis, we have shown that if PMBV performed by experienced operator, success of PMBV will be similar between patients regardless of MWS. This finding was consistent with a previous study of Ekinci et al. (22) .
Inoue balloon catheter is characterized by its low complication rate in comparison to the reported results of double balloon technique (23) . CVA, pericardial tamponade and procedure related death were not encountered in our study, that is significantly lower compared to previous reports, which range between 1% and 2% (2, 3). We recommend to perform transesophageal echocardiography for all patients before PMBV regardless of AF or with prior thromboembolic history and also when the mitral valve morphology was not adequately assessed by transthoracic echocardiography.
In our study, we established that preprocedural higher peak gradient, higher MVA, lower mean and peak transmitral gradient and higher percent improvement in MVA immediately after the procedure were associated with better long-term outcome. Furthermore, we demonstrated that mitral morphology and preprocedural MVA were not related with long-term event-free survival. According to our study findings; when at least 60% of improvement in MVA occurs with PMBV, restenosis rate in the long term will be lower than that of patients whose improvement in MVA is below 60%. In other studies, the increase in MVA also has been defined as a predictor of restenosis and 1.8 cm 2 has been reported as a cut off value for postprocedural MVA (24) . Mitral valve anatomy assessed by echocardiography has been indicated as a significant predictor of immediate procedural success and long-term restenosis (19, 24) . We did not find a relationship between MWS and both acute procedural results and long-term restenosis.
Differences in age, clinical characteristics, and valve morphology may also account for the worse long-term event-free survival in the above reports from the United States and Europe compared with our series; accordingly, the long-term results of our study population cannot be extrapolated to the older-patient populations reported in the literature.
Study limitations
One limitation of this study is that only 63 patients completed long-term echocardiographic follow-up, but as the demographic characteristics and immediate post-procedural findings were similar to those of the main study population, this should not affect overall study findings. However, the excellent long-term results of this study cannot be extrapolated to the older patient populations seen in Europe and the USA.
Conclusion
It was concluded that PMBV provides excellent long-term outcomes for up to five years in patients with MS and if the procedure performed by experienced operator and high volume center although unfavorable mitral valve morphology, acceptable hemodynamic and symptomatic relief are achievable.
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